PRA Health Sciences
4141 ParkLake Avenue, Suite 530
233 articles with PRA Health Sciences
PRA Health Sciences appoints senior FDA official to lead new Global Center of Excellence for Decentralized Clinical Trial Strategy
Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA’s industry-leading DCT practice
$796.3 million of total revenue; representing growth of 2.0% at actual foreign exchange rates and 1.3% on a constant currency basis
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today it has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to be a member of its updated Clinical Studies Network (CSN).
PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials
The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials
PRA Health Sciences, Inc. announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective September 14, 2020.
PRA Health Sciences, Inc. Reports Second Quarter 2020 Results and Provides Third Quarter and Full Year 2020 Guidance
PRA Health Sciences, Inc. reported financial results for the quarter ended June 30, 2020.
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2020 results after the market closes on Thursday, August 6, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service.
PRA Health Sciences, Inc. Reports First Quarter 2020 Results, Withdraws Full Year 2020 Guidance Due to Uncertain COVID-19 Impact and Provides Second Quarter 2020 Guidance
PRA Health Sciences, Inc. reported financial results for the three months ended March 31, 2020..
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2020 results after the market closes on Thursday, April 30, 2020.
Symphony Health to provide free access to new MetysTM COVID-19 Module for U.S. based life sciences industry during pandemicMetys COVID-19 Module delivers pharmaceutical market analytics and intelligence quickly through a single access point
PRA Health Sciences announced that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly released MetysTM COVID-19 Module available to the U.S. life science industry at no charge.
PRA Health Sciences expands remote clinical study support with its Mobile Health Platform during COVID-19 pandemicPRA’s Mobile Health Platform delivers virtual solutions for sites and patients enrolled in trials
As a response to the ongoing global COVID-19 pandemic, PRA Health Sciences announced the expansion of its industry-leading Mobile Health Platform for remote clinical monitoring, adding several new capabilities that address sponsor needs for COVID-19 virtual study support.
Life sciences customers will gain flexibility to build bespoke, fit-for-purpose data assets and strategies to support the development and delivery of life-enhancing drugs
PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2019 Results and Provides First Quarter and Full Year 2020 Guidance
PRA Health Sciences, Inc. reported financial results for the quarter and year ended December 31, 2019..
Perspecta and PRA Health Sciences complete successful modernization of Million Veteran Program for U.S. Department of Veterans Affairs
MVP is a national, voluntary research program funded by the VA Office of Research and Development.
PRA Health Sciences, Inc. reported financial results for the quarter ended September 30, 2019.
An industry first, the volunteer committee will evaluate unique patient needs and advise PRA on how clinical trials can be adapted for rare disease patients
PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – MetysTM (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract research organization (CRO).
PRA Health Sciences, Inc. Expands Service Provisions to Pharmaceutical and Biotech Companies Through Buyout of Takeda Joint Venture in Japan
PRA Health Sciences, Inc. (NASDAQ: PRAH, “PRA”) announced the buyout of its joint venture with Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) in Japan, which was completed on June 1.